EMEA-003551-PIP01-23 - paediatric investigation plan

maplirpacept

Key facts

• Active substance:
  maplirpacept
• Therapeutic area:
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
• Decision number:
  P/0125/2024
• PIP number:
  EMEA-003551-PIP01-23
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of Multiple Myeloma
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/04/2024
• Compliance check done:
  No

Decision

P/0125/2024: EMA decision of 11 April 2024 on the granting of a product specific waiver for maplirpacept (EMEA-003551-PIP01-23)

Adopted Reference Number: EMA/143927/2024